Processes that provide economical, safe, and green access to chemically modified oligonucleotides is of paramount importance in the manufacturing of therapeutic drugs. So far, ten oligonucleotides have been approved by the US FDA and over hundred products are undergoing human clinical trials. To support the anticipated large-scale commercial demand of these molecules, we have developed improved synthetic methodologies following the twelve principles of green chemistry. This presentation will summarize our efforts in enabling environmentally friendly chemistry.

Subject area:
Biologics

Objectives (If applicable):
N/A

Target Audience (If applicable):
Analytical chemists
QA/QC analysts
R&D scientists, managers
Team members in CMC development projects
Manufacturing scientists, managers
Regulatory affairs specialists
Contract research organizations
Contract manufacturing organizations